How does SpotitEarly collaborate with researchers and hospital systems?

At SpotitEarly, collaboration is at the heart of innovation. We’re working hand-in-hand with leading researchers, healthcare organisations and hospitals worldwide to revolutionize cancer screening. By uniting our combined expertise across disciplines, we aim to push the boundaries of what’s possible in early cancer detection and ensure our solutions are backed by the most rigorous science.

These partnerships demonstrate our shared ambition to make early detection more accurate, accessible and impactful. Here’s how SpotitEarly works with partners to build a network that is advancing the science of cancer screening.

Partnering with researchers SpotitEarly’s groundbreaking approach to the early detection of multiple different cancer types combines the olfactory capabilities of specially trained dogs with the analytical power of AI. Our success is driven by a team of highly knowledgeable experts – from researchers to the CEO and the dog trainers – who are all leaders in their respective fields. Together with top research partners, including specialists in design, oncology and data analysis, we continually validate and refine this unique methodology to deliver our innovative and impactful solutions.

Through our partnerships with other medical organizations, we:

• Conduct robust clinical trials that validate the efficacy and reliability of our tests.
• Publish peer-reviewed studies that establish a strong scientific foundation for our methods.
• Accelerate the commercialization and distribution of our unique products.

These collaborations not only support our proprietary approach and technology, but also contribute valuable insights to the broader medical and scientific community. And, according to Roi Ophir, Chairman and Co-founder of SpotitEarly, the business can also make existing screening programs “more efficient and more affordable for our partners.”

Collaborating with hospitals Healthcare systems play a critical role in our mission to make early cancer detection a routine part of healthcare. By working directly with healthcare institutions and professionals, SpotitEarly ensures that our solutions integrate seamlessly into clinical workflows.

Some key aspects of our current collaborations include:

• Our clinical trials feature the participation of diverse patient groups, enabling us to ensure our tests are accessible and inclusive to the widest range of demographics and cancer types.
• By deploying our technology in clinical settings, we gather critical data on its performance in real-world scenarios, ensuring we can meet the needs of both patients and providers.
• This all helps us streamline our screening processes so that our breath collection kits are simple, non-invasive and easy for patients to use.

Driving progress together Running clinical trials forms the backbone of our efforts to transform cancer screening. These are vital for SpotitEarly because they provide the rigorous scientific validation needed to demonstrate the accuracy, reliability and safety of our unique approach. Furthermore, the tests help us to improve by setting benchmarks to make sure we can produce consistent reliable results

Notably, SpotitEarly has already conducted and published a significant, peer-reviewed double-blind clinical trial integrating canines and AI for cancer detection. This study, which included over 1,300 participants, ran across three clinical sites in Israel and demonstrated an impressive detection rate of over 93% across four common cancer types.

Building on this foundation, we have announced two further trials with international healthcare partners. Called the Pink and White Studies, these are two landmark initiatives designed to further validate and refine our approach.

The Pink Study leverages breath samples to advance the early detection of breast cancer. This trial is being conducted in cooperation with the University of Pennsylvania (UPenn) and the Tel- Aviv Sourasky Medical Center

Meanwhile, the White Study aims to develop advanced clinical techniques to identify lung cancer in its early stages. Both studies emphasize inclusivity and will feature diverse patient populations to ensure our technology works across demographics and disease variations.

These trials wouldn’t be possible without the support of our network of partner institutions. Such collaborations ensure that our research is comprehensive, diverse and focused on achieving meaningful results for patients worldwide. Of course, they also validate that we can adapt it to health institutions’ needs and processes, allowing us to integrate into the market quickly and seamlessly.

Future collaborations As we continue to expand our network, SpotitEarly remains committed to forging partnerships that drive innovation and improve outcomes. We’re not just building a network of researchers and hospitals; we’re creating a global coalition dedicated to early cancer detection.

Through these new collaborations, we aim to:

• Expand access to life-saving screening for underserved populations and regions worldwide.
• Develop next-generation tools that address some of the limitations of traditional cancer screening methods, such as accessibility, ease of use and affordability.
• Improve the robustness of clinical trials. Clearly, the more collaborations we undertake, the more samples we can test and the more data we can generate.
• Inspire a new standard of care where the early detection of cancer becomes a fundamental part of healthcare worldwide.

Join the mission

At SpotitEarly, we believe that collaboration is key to creating healthier futures. Together with our partners, we’re transforming the landscape of cancer screening — one breakthrough at a time. If you’re interested in joining us on this journey, contact us today to learn more and let’s make early detection a reality for all.